Detection and Prevalence of Human Papillomavirus (HPV) in Seminal Plasma and/or on Sperm in Men Undergoing Treatment With IVF/ICSI.
Key facts
- Who runs it
- Vastra Gotaland Region
- Where
- Sweden1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 260 people enrolled
- Started
- 1 Jan 2023
- Ended
- 28 Mar 2024
- Type of study
- Observational, 2 groups
- Treatments tested
- HPV exposure
- Record updated
- 26 April 2024
Who can take part
- Age
- 18 years to 60 years
- Sex
- Men only
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Over the course of one year, the study will include men undergoing infertility treatment with IVF/ICSI and fresh ejaculated sperm at Sahlgrenska University Hospital (SU), Gothenburg, Sweden
Who cannot take part
- Men undergoing sperm freezing for fertility preservation purposes or possessing previously frozen sperm
- Men for whom treatment with preimplantation genetic testing (PGT) or egg donation is planned
- Men undergoing IVF/ICSI treatments with surgically extracted sperm
- Sperm donors
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This observational study aims to investigate the presence of HPV DNA in semen samples from men undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment. It focuses on understanding the impact of HPV on male fertility and embryo development following IVF/ICSI. The primary goal is to determine the prevalence of HPV-positive (HPV+) semen samples among men seeking infertility treatment with IVF/ICSI. Additionally, the study aims to compare semen characteristics between HPV-positive and HPV-negative (HPV-) samples and assess the embryological outcomes after IVF/ICSI in these two groups.
Read full original descriptionShow less
Participants in this study will include men receiving IVF/ICSI treatment and providing fresh ejaculated sperm at Sahlgrenska University Hospital in Gothenburg, Sweden, over one year. Those undergoing treatments with surgically extracted sperm, sperm freezing for fertility preservation, or planning treatments involving preimplantation genetic testing or egg donation will be excluded.
The study will involve analyzing HPV DNA in semen samples through PCR, utilizing the most effective method for HPV DNA detection previously identified in a pilot study. Sperm samples collected during infertility investigations and IVF/ICSI treatments will undergo gradient centrifugation to separate different components. A portion of the sperm sample will be preserved for PCR analysis to detect HPV DNA, while the rest will be used for IVF/ICSI procedures. The results from the PCR analyses will be correlated with semen characteristics and the outcomes of IVF/ICSI treatment. Furthermore, the samples will be stored for potential future analyses related to HPV-related biomarkers for up to 5 years at Biobank.
The 2 groups in the trial
- Men with HPV-positive (HPV+) semen samples
Treatment: HPV exposure
- Men with HPV-negative (HPV-) semen samples
Treatment: HPV exposure
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Detection and Prevalence of Human Papillomavirus (HPV) in Seminal Plasma and/or on Sperm in Men Undergoing Treatment With IVF/ICSI in Southwestern Sweden: a Prospective Study.
- Publications
- Semen HPV and IVF: insights from infection prevalence to embryologic outcomes.Journal of assisted reproduction and genetics, 2025
- Record updated
- 26 April 2024